Zöllner, Johann Philipp
Franz, David Neal
Hertzberg, Christoph
Nabbout, Rima
Rosenow, Felix
Sauter, Matthias
Schubert-Bast, Susanne
Wiemer-Kruel, Adelheid
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Funding for this research was provided by:
Hessisches Ministerium für Wissenschaft und Kunst (LOEWE CePTER)
Article History
Received: 28 July 2019
Accepted: 19 November 2019
First Online: 21 January 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: JPZ reports a speaker’s honorarium from Eisai.DNF reports travel support and honoraria from Novartis. His employer has also received support for clinical trials and consulting work from Novartis.RN reports speakers and board fees from GW Pharma, Biocodex, Novartis, Eisai, Nutricia, Zogenix, UCB, Advicenne, Biogene, Stoke and unrestricted educational grants from UCB, Eisai and GW Pharma.FR reports personal fees from Eisai, GW-Pharma and Desitin Pharma, personal fees and others from Novartis, personal fees from Medtronic, personal fees from Cerbomed, personal fees from Shire, grants from the European Union, the German Minister for Education and Research (BMBF) the LOEWE Programm of the state of Hesse and grants from the Deutsche Forschungsgemeinschaft (DFG) and the Detlev-Wrobel-Fonds for Epilepsy Research .MS reports personal fees and grants from Novartis.SSB reports personal fees from UCB, Desitin Arzneimittel, Novartis, Zogenix, LivaNova, and Eisai.AWK reports grants and personal fees from Novartis and Nutricia, and only personal fees from Desitin Arzneimittel, Dr. Schär, Vitaflo, UCB Pharma.AS reports personal fees and grants from Desitin Arzneimittel, Eisai, GW pharmaceuticals, LivaNova, Marinus pharmaceuticals, Medtronic, Sage Therapeutics, UCB Pharma, and Zogenix.CH declares that he has no competing interests.